PMID- 23891772
OWN - NLM
STAT- MEDLINE
DCOM- 20140926
LR  - 20181202
IS  - 1873-3441 (Electronic)
IS  - 0939-6411 (Linking)
VI  - 85
IP  - 3 Pt A
DP  - 2013 Nov
TI  - Enhanced accumulation of curcumin and temozolomide loaded magnetic nanoparticles 
      executes profound cytotoxic effect in glioblastoma spheroid model.
PG  - 452-62
LID - S0939-6411(13)00258-0 [pii]
LID - 10.1016/j.ejpb.2013.07.013 [doi]
AB  - Glioblastomas (GBMs) are highly lethal primary brain tumours. Treatment of these 
      malignant gliomas remains ineffective as these are extremely resistant to 
      chemotherapeutic applications. Furthermore, combination therapy for cancer 
      treatment is becoming more popular because it generates synergistic anticancer 
      effects, by reducing individual drug-related toxicity and associated side 
      effects. Currently, magnetic nanoparticles (MNPs) based drug delivery system has 
      attracted much more attention owing to its intrinsic magnetic properties and drug 
      loading capacity. In the present study, MNPs based drug delivery approach for 
      co-delivering of potent chemotherapeutic drugs such as Curcumin (herbal drug) and 
      Temozolomide (DNA methylating agent) has been implemented. The dual drug loaded 
      MNPs formulations were evaluated in two-dimensional (2-D) monolayer culture and 
      three-dimensional (3-D) tumour spheroid culture of T-98G cells for understanding 
      the therapeutic discrepancy. The dual drug loaded MNPs formulations demonstrated 
      higher cytotoxic effect than single drug loaded MNPs formulations as compared to 
      their corresponding native drugs in 2-D and 3-D culture. The combination index 
      (CI) analysis revealed synergistic mode of action of dual drug loaded MNPs 
      formulations, which was further confirmed by cell death induction assay mediated 
      by acridine orange (AO)/propidium iodide (PI) staining, illustrating higher 
      efficacy of the formulation towards GBM therapy.
CI  - Copyright (c) 2013. Published by Elsevier B.V.
FAU - Dilnawaz, Fahima
AU  - Dilnawaz F
AD  - Laboratory of Nanomedicine, Institute of Life Sciences, Bhubaneswar, India.
FAU - Sahoo, Sanjeeb Kumar
AU  - Sahoo SK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130725
PL  - Netherlands
TA  - Eur J Pharm Biopharm
JT  - European journal of pharmaceutics and biopharmaceutics : official journal of 
      Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
JID - 9109778
RN  - 36015-30-2 (Propidium)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - F30N4O6XVV (Acridine Orange)
RN  - IT942ZTH98 (Curcumin)
RN  - YF1K15M17Y (Temozolomide)
SB  - IM
MH  - Acridine Orange/chemistry
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & 
      dosage/pharmacokinetics/pharmacology
MH  - Apoptosis/drug effects
MH  - Brain Neoplasms/*drug therapy
MH  - Cell Culture Techniques
MH  - Cell Death/drug effects
MH  - Cell Line, Tumor
MH  - Curcumin/administration & dosage
MH  - Dacarbazine/administration & dosage/analogs & derivatives
MH  - *Drug Delivery Systems
MH  - Drug Synergism
MH  - Glioblastoma/*drug therapy/pathology
MH  - Humans
MH  - Magnetics
MH  - Nanoparticles
MH  - Propidium/chemistry
MH  - Staining and Labeling
MH  - Temozolomide
OTO - NOTNLM
OT  - Cell death
OT  - Cytotoxicity
OT  - Glioblastoma
OT  - Magnetic nanoparticles
OT  - Synergistic
OT  - Tumour spheroids
EDAT- 2013/07/31 06:00
MHDA- 2014/09/27 06:00
CRDT- 2013/07/30 06:00
PHST- 2013/02/19 00:00 [received]
PHST- 2013/07/16 00:00 [revised]
PHST- 2013/07/17 00:00 [accepted]
PHST- 2013/07/30 06:00 [entrez]
PHST- 2013/07/31 06:00 [pubmed]
PHST- 2014/09/27 06:00 [medline]
AID - S0939-6411(13)00258-0 [pii]
AID - 10.1016/j.ejpb.2013.07.013 [doi]
PST - ppublish
SO  - Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):452-62. doi: 
      10.1016/j.ejpb.2013.07.013. Epub 2013 Jul 25.